Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453284 | 1.00 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP2C9ALOX15CYP1A2 | |
| SCHEMBL24257690 | 0.85 | CNR1 (0.39) | CNR1PDE2AGRM2 | |
| SCHEMBL30452359 | 0.85 | CNR1 (0.39) | CNR1PDE2AGRM2 | |
| SCHEMBL30453400 | 0.85 | NPC1 (0.41) | CNR1MAPT | |
| SCHEMBL24257586 | 0.85 | NPC1 (0.41) | CNR1MAPT | |
| SCHEMBL30546893 | 0.82 | CYP11B1 (0.42) | CYP11B1CYP11B2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL24257819 | 0.80 | HSD17B10 (0.43) | KDM4ECNR1MAPT | |
| SCHEMBL30546879 | 0.80 | HSD17B10 (0.43) | KDM4ECNR1MAPT | |
| SCHEMBL24257562 | 0.76 | MAOB (0.47) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30546831 | 0.76 | MAOB (0.47) | CYP2C9CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | CYP11B1 809/4885CYP11B2 703/4885CYP2C9 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.